Calithera Biosciences Inc
NASDAQ:CALA
Calithera Biosciences Inc
Long-Term Debt
Calithera Biosciences Inc
Long-Term Debt Peer Comparison
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Calithera Biosciences Inc
NASDAQ:CALA
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$63.8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$21.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$60.1B
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$361.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
31%
|
CAGR 10-Years
18%
|
See Also
What is Calithera Biosciences Inc's Long-Term Debt?
Long-Term Debt
0
USD
Based on the financial report for Dec 31, 2022, Calithera Biosciences Inc's Long-Term Debt amounts to 0 USD.